Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Opthea ( (AU:OPT) ) has provided an update.
Opthea has disclosed a change in director Katherine Connell’s interests following the issue of 41 million unquoted options under the company’s Non-Executive Directors Share and Option Plan, which was approved at the 11 November 2025 annual general meeting. The new options, exercisable at a 20% premium to the 10-day volume-weighted average price once Opthea’s securities are reinstated to ASX quotation and expiring in November 2035, significantly increase Connell’s equity-linked exposure and underscore the company’s use of incentive-based compensation to align board oversight with shareholder value.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is an Australian-listed biotechnology company focused on developing therapies for eye diseases. The company’s primary activities center on research and development of ophthalmic treatments, targeting conditions affecting vision within global healthcare and pharmaceutical markets.
YTD Price Performance: -25.93%
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
For detailed information about OPT stock, go to TipRanks’ Stock Analysis page.